For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Summary of Significant Accounting Policies - Segment Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023 item	Jun. 30, 2022	Jun. 30, 2023 segment item	Jun. 30, 2022
Segment Information
Number of operating segments \| segment			1
Other customers \| Revenue \| Customer concentration
Segment Information
Percentages of revenue recognized			0.00%	0.00%
Specialty distributors and pharmacy providers \| Revenue \| Customer concentration
Segment Information
Number of operating segments \| item	4		4
Percentages of revenue recognized	93.00%		80.00%
Roche \| Revenue \| Customer concentration
Segment Information
Percentages of revenue recognized	7.00%	50.00%	8.00%	26.00%
Huadong \| Revenue \| Customer concentration
Segment Information
Percentages of revenue recognized		50.00%		56.00%
Lilly \| Revenue \| Customer concentration
Segment Information
Percentages of revenue recognized				17.00%
Vertex Pharmaceuticals Incorporated [Member] \| Revenue \| Customer concentration
Segment Information
Percentages of revenue recognized			11.00%